Accessing psilocybin in the UK
At the PSYCH Symposium on 11 May, industry leaders will connect and collaborate to expedite access to psychedelic-based healthcare across Europe.
Accelerating the adoption and accessibility of psychedelic healthcare is crucial to drive innovation in mental healthcare and improved patient outcomes worldwide.
The discovery and development of psychedelic medicines in Europe are currently hindered by regulations that restrict their access. Despite a mounting body of clinical evidence demonstrating its medical efficacy, psilocybin remains a Schedule 1 substance in the UK.
The Conservative Drug Policy Reform Group (CDPRG) is championing the campaign to reschedule psilocybin, with Chair and Member of Parliament Crispin Blunt speaking at the PSYCH Symposium on Wednesday, 11 May.
Ahead of the seminal event, PSYCH spoke with Blunt and Timmy Davis, Psilocybin Rescheduling Project Manager at the CDPRG, on the need to facilitate access to psilocybin in the UK for medical research.READ MORE